Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFRY ALAN JACQMEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1588624761
CMS profile
117341
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$193.80

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $193.80 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $126.08 1
AstraZeneca Pharmaceuticals LP $67.72 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFRY ALAN JACQMEIN

NPI 1588624761 · CMS profile ID 117341

Allopathic & Osteopathic Physicians / Family Medicine

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $193.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $126.0811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141579567 CMS
AstraZeneca Pharmaceuticals LP $67.7205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105715512 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $193.80 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,267,086.60 104
PY2024 Recipient $1,250.00 1
PY2024 Principal investigator $2,152,633.93 77
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $2,337,900.80 1,040
PY2022 Principal investigator $878,603.36 715
PY2021 Principal investigator $421,556.50 35
PY2020 Principal investigator $639,049.71 93
PY2019 Principal investigator $963,118.36 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $200.13 12/26/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742897011
Principal investigator 1 AbbVie Inc. $950.60 12/16/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721200741
Principal investigator 1 Seqirus USA Inc $22,866.30 12/08/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691703
Principal investigator 1 Seqirus USA Inc $59,071.50 11/17/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691699
Principal investigator 1 Seqirus USA Inc $516.00 11/10/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691691
Principal investigator 1 Seqirus USA Inc $1,408.00 11/03/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691719
Principal investigator 1 Seqirus USA Inc $5,500.00 11/03/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults No dispute reported 06/30/2026 746691783
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/21/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734924483
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/21/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734927147
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/21/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525985
Principal investigator 1 GlaxoSmithKline, LLC. $2,878.20 10/21/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525995
Principal investigator 1 PFIZER INC. $2,250.00 10/17/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742926167
Principal investigator 1 PFIZER INC. $2,250.00 10/08/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742926171
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 10/07/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734925843
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 10/07/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734929451
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 10/07/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525991
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 10/07/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525997
Principal investigator 1 GlaxoSmithKline, LLC. $1,439.10 10/01/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734926233
Principal investigator 1 GlaxoSmithKline, LLC. $1,439.10 10/01/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965526039
Principal investigator 1 GlaxoSmithKline, LLC. $5,756.40 09/23/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734908989
Principal investigator 1 AbbVie Inc. $1,537.80 09/17/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721186165
Principal investigator 1 AbbVie Inc. $1,308.10 08/18/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721181263
Principal investigator 1 AbbVie Inc. $3,625.80 07/15/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721175855
Principal investigator 1 AbbVie Inc. $1,015.40 06/15/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721171133
Principal investigator 1 PFIZER INC. $325.00 06/13/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742957421
Principal investigator 1 AbbVie Inc. $283.10 05/20/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721166473
Principal investigator 1 SANOFI PASTEUR INC. $250.00 05/14/2020 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744030029
Principal investigator 1 PFIZER INC. $11,175.33 05/08/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937781
Principal investigator 1 PFIZER INC. $1,084.50 05/07/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742934549
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 05/04/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734909725
Principal investigator 1 PFIZER INC. $3,356.16 04/30/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968817
Principal investigator 1 PFIZER INC. $1,177.14 04/29/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968757
Principal investigator 1 PFIZER INC. $1,207.83 04/28/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969066
Principal investigator 1 GlaxoSmithKline, LLC. $1,545.30 04/24/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903781
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 04/22/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903409
Principal investigator 1 PFIZER INC. $3,019.74 04/22/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968759
Principal investigator 1 AbbVie Inc. $750.00 04/20/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721161223
Principal investigator 1 AbbVie Inc. $832.60 04/20/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721161225
Principal investigator 1 PFIZER INC. $600.00 04/18/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937785
Principal investigator 1 PFIZER INC. $750.00 04/18/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968823
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 04/15/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903337
Principal investigator 1 AbbVie Inc. $780.00 04/10/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721160347
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 04/08/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734901115
Principal investigator 1 GlaxoSmithKline, LLC. $4,399.20 04/08/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734901957
Principal investigator 1 GlaxoSmithKline, LLC. $8,892.00 04/08/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734904267
Principal investigator 1 SANOFI PASTEUR INC. $19,000.00 04/07/2020 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744029991
Principal investigator 1 Biogen, Inc. $253,520.00 04/02/2020 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 736753857
Principal investigator 1 GlaxoSmithKline, LLC. $2,398.50 04/01/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903407
Principal investigator 1 PFIZER INC. $1,154.72 03/31/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968821
Principal investigator 1 GlaxoSmithKline, LLC. $90.00 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908897
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908899
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 753908901
Principal investigator 1 GlaxoSmithKline, LLC. $90.00 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525913
Principal investigator 1 GlaxoSmithKline, LLC. $1,918.80 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525979
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 03/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525981
Principal investigator 1 AbbVie Inc. $1,973.00 03/19/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721156101
Principal investigator 1 GlaxoSmithKline, LLC. $1,971.90 03/18/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 753909691
Principal investigator 1 GlaxoSmithKline, LLC. $1,971.90 03/18/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525915
Principal investigator 1 PFIZER INC. $1,244.88 03/17/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968887
Principal investigator 1 PFIZER INC. $1,599.32 03/12/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968751
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 03/11/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 753909689
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 03/11/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525911
Principal investigator 1 PFIZER INC. $266.50 03/11/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937789
Principal investigator 1 AbbVie Inc. $2,535.00 03/10/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721155265
Principal investigator 1 PFIZER INC. $5,644.14 02/27/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969117
Principal investigator 1 PFIZER INC. $8,191.78 02/27/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742969553
Principal investigator 1 AbbVie Inc. $1,300.00 02/26/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721152167
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 02/25/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734900619
Principal investigator 1 GlaxoSmithKline, LLC. $1,012.50 02/25/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525983
Principal investigator 1 PFIZER INC. $5,054.30 02/25/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742968753
Principal investigator 1 PFIZER INC. $7,124.40 02/25/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968815
Principal investigator 1 AbbVie Inc. $75.00 02/24/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721151797
Principal investigator 1 GlaxoSmithKline, LLC. $9,266.40 02/12/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734900801
Principal investigator 1 GlaxoSmithKline, LLC. $9,266.40 02/12/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525917
Principal investigator 1 PFIZER INC. $533.00 01/31/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742937423
Principal investigator 1 PFIZER INC. $907.72 01/29/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742900257
Principal investigator 1 PFIZER INC. $1,306.63 01/29/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900261
Principal investigator 1 GlaxoSmithKline, LLC. $1,065.60 01/28/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734902431
Principal investigator 1 GlaxoSmithKline, LLC. $1,065.60 01/28/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525987
Principal investigator 1 SANOFI PASTEUR INC. $26,500.00 01/28/2020 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 No dispute reported 06/30/2026 744029955
Principal investigator 1 GlaxoSmithKline, LLC. $2,131.20 01/22/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734903183
Principal investigator 1 GlaxoSmithKline, LLC. $2,131.20 01/22/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525989
Principal investigator 1 AbbVie Inc. $3,140.20 01/21/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
M16-100 No dispute reported 06/30/2026 721146043
Principal investigator 1 PFIZER INC. $6,329.39 01/21/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742900301
Principal investigator 1 PFIZER INC. $5,306.79 01/21/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900625
Principal investigator 1 Biogen, Inc. $36,535.00 01/10/2020 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease No dispute reported 06/30/2026 736753855
Principal investigator 1 GlaxoSmithKline, LLC. $1,252.80 01/08/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734901665
Principal investigator 1 GlaxoSmithKline, LLC. $3,434.40 01/08/2020 Non-covered Recipient Entity
CENTER FOR CLINICAL RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734904463
Principal investigator 1 GlaxoSmithKline, LLC. $3,434.40 01/08/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965525993
Principal investigator 1 GlaxoSmithKline, LLC. $1,252.80 01/08/2020 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A PHASE I/II, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTICEN No dispute reported 06/30/2026 965526041
Principal investigator 1 PFIZER INC. $5,348.21 01/07/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900267
Principal investigator 1 PFIZER INC. $1,446.80 01/07/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742900305
Principal investigator 1 PFIZER INC. $11,933.10 01/04/2020 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742900263